Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
5 raisons identifiées
Auteur de référence en rhumatologie
32 articles scientifiques publiés — un praticien à la pointe de la recherche
Encadrant universitaire
Forme la prochaine génération de rhumatologues (4 thèses dirigées)
Expérience confirmée
40 ans d'exercice en rhumatologie — recul clinique solide
Disponibilité géographique
2 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
131.9 rhumatos / 100 000 hab. — département bien doté
40ans d'exercice (thèse 1986)
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
✨ Génération du profil synthétique IA en cours…
Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.
Les cytokines inflammatoires et les canaux ioniques dans la tumorigénèse du cancer colorectal : rôle du TNF et modulation du KCa3.1
2019Doctorant·e : Sajida Ibrahim
Etude de l'expression de recombinases néogéniques dans le cancer colorectal
2013Doctorant·e : Ahmed Arnaoty
Relation dose-concentration-effet du cétuximab et du bévacizumab dans le traitement du cancer colorectal métastatique
Doctorant·e : Sarah Lobet
Epidémiologie des tumeurs neuroendocrines sécrétrices ou non d'androgènes et leurs impacts sur la fertilité pré et post thérapeutique
Doctorant·e : Arnaud Dosda
Source theses.fr — signal de direction d'équipe / statut PU-PH (à confirmer via le site universitaire).
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
51
51 articles ont été cités au moins 51fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
12 853
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
479
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
174
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Université de Tours · Inserm · Centre Hospitalier Universitaire de Tours
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Analysis of the relationship between body composition and the pharmacokinetics of panitumumab in the treatment of localized squamous cell carcinoma of the anus – An ancillary study of the FFCD0904 phase I and II trial
2026ArticleBiomedicine and Pharmacotherapy
Data on microRNA transcriptomic signatures, predicted gene targets and pathway analysis in response to cetuximab or panitumumab in colorectal cancer cells
2026ArticleData in Brief
Efficacy of targeted therapies for metastatic small bowel adenocarcinoma treatment: a retrospective study by AGEO
2026ArticleEuropean Journal of Cancer
Évaluation qualitative d’une stratégie d’éducation des patients à risque très élevé de cancer colorectal au dépistage de leurs apparentés
2026ArticleSanté Publique
Clinical and Pathological Features of EC-cell Familial Small Intestine Neuroendocrine Tumors: A Nationwide Cohort From the French GTE-RENATEN Network
2026ArticleEndocrine Pathology
ALTOPANC: Local ablative therapies in oligometastatic pancreatic adenocarcinoma—A bi-national French-Belgian retrospective study.
2026ArticleJournal of Clinical Oncology
Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: the RASINTRO prospective multicenter study
2025ArticleJNCI: Journal of the National Cancer Institute
A multicentric national phase II trial assessing TIslelizumab in monotherapy for patients with Hepatocellular Carcinoma Child-Pugh B and ALBI grade 1 or 2 liver function score: The UCGI 41 HESTIA TRIAL DESIGN AND PRELIMINARY SAFETY Data
2025ArticleDigestive and Liver Disease
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CHRU TROUSSEAU - CHAMBRAY
AV DE LA REPUBLIQUE, 37170 CHAMBRAY LES TOURS
SERVICE DE SOINS SNCF
41 R GRECOURT, 37000 TOURS
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
PURPOSE GEMPAX was an open-label, randomized phase III clinical trial designed to assess the efficacy and tolerability of gemcitabine plus paclitaxel versus gemcitabine alone as second-line treatment for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who previously received 5-fluorouracil, oxaliplatin, and irinotecan. METHODS Patients with histologically or cytologically confirmed mPDAC were randomly assigned (2:1) to receive GEMPAX (paclitaxel 80 mg/m2 + gemcitabine 1,000 mg/m2; IV; once at day (D) 1, D8, and D15/arm A) or gemcitabine (arm B) alone once at D1, D8, and D15 every 28 days until progression, toxicity, or patient's decision. The primary end point was overall survival (OS). Secondary end points included progression-free survival (PFS), objective response rate (ORR), quality of life, and safety. RESULTS Overall, 211 patients (median age, 64 [30-86] years; 62% male) were included. After a median study follow-up for alive patients of 13.4 versus 13.8 months in arm A versus arm B, the median OS (95% CI) was 6.4 (5.2 to 7.4) versus 5.9 months (4.6 to 6.9; hazard ratio [HR], 0.87 [0.63 to 1.20]; P = 0.4095), the median PFS was 3.1 (2.2 to 4.3) versus 2.0 months (1.9 to 2.3; HR, 0.64 [0.47 to 0.89]; P = 0.0067), and the ORR was 17.1% (11.3 to 24.4) versus 4.2% (0.9 to 11.9; P = 0.008) in arm A versus arm B, respectively. Overall, 16.7% of patients in arm A and 2.9% in arm B discontinued their treatment because of adverse events (AEs). One grade 5 AE associated with both gemcitabine and paclitaxel was reported in arm A (acute respiratory distress), and 58.0% versus 27.1% of patients experienced grade ≥3 treatment-related AEs in arm A versus arm B, among which 15.2% versus 4.3% had anemia, 15.9% versus 15.7% had neutropenia, 19.6% versus 4.3% had thrombocytopenia, 10.1% versus 2.9% had asthenia and 12.3% versus 0.0% had neuropathy. CONCLUSION While GEMPAX did not meet the primary end point of OS versus gemcitabine alone in patients with mPDAC in the second-line setting, both PFS and ORR were significantly improved.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
PURPOSE More than 30% of patients with pancreatic cancer are unresectable because of the local extension with a median overall survival (OS) of <1 year. Combination of fluorouracil (FU), oxaliplatin, and irinotecan (FOLFIRINOX) is superior to gemcitabine in the treatment of metastatic pancreatic cancer, but standard of care remains gemcitabine in locally advanced pancreatic cancer (LAPC). METHODS Patients with histologically proven LAPC not suitable for surgery, Eastern Cooperative Oncology Group WHO performance status (PS) ≤1 were eligible. Random assignment was stratified by center, tumor localization (pancreas head yes/no), WHO PS (0 v 1), and age (≤60 years v >60 years). Patients received FOLFIRINOX or gemcitabine for 6 months. The primary end point was progression-free survival (PFS). Main secondary end points were OS, time to treatment failure, quality of life, and safety. One hundred seventy patients (142 events) were needed to detect an increase of 3 months in PFS with 80% power (log-rank test, 5% two-sided α). RESULTS One hundred seventy one patients age 35-84 years were included and followed for a maximum of 5 years. With a median follow-up of 59.6 months (95% CI, 42.3 to not reached), 168 events were observed and the median PFS was 9.7 months (95% CI, 7.0 to 11.7) with FOLFIRINOX versus 7.7 months (95% CI, 6.2 to 9.2) with gemcitabine, hazard ratio (HR), 0.7 (95% CI, 0.5 to 1.0), P = .04. The median OS was 15.7 months (95% CI, 11.9 to 20.4) in the FOLFIRINOX group versus 15.4 months (95% CI, 11.7 to 18.6) in the gemcitabine group, HR, 1.02 (95% CI, 0.73 to 1.43), P = .95. CONCLUSION Results confirm that FOLFIRINOX improves PFS significantly compared with gemcitabine and is well tolerated in LAPC. No significant difference in OS was observed between both groups.
The Lancet. Oncology · 2025
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
European journal of cancer (Oxford, England : 1990) · 2026 · Journal Article
Boisteau E, Boilève A, Tougeron D, Vernerey D, et al.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2026 · Journal Article
Lobet S, Ternant D, Lepage C, Le Malicot K, et al.
Endocrine pathology · 2026 · Journal Article
Hunaut T, Gérard L, Hercent A, Hentic O, et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025 · Journal Article
Fodil-Cherif S, Hadoux J, Mercier O, Benitez JC, et al.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2025 · Journal Article
Ye-Tran X, Bouattour M, Fresneau B, Turpin A, et al.
The oncologist · 2025 · Journal Article
Evrard C, Pelras A, Rivet S, Bachet JB, et al.
JHEP reports : innovation in hepatology · 2025 · Journal Article
Adamus N, Edeline J, Henriques J, Fares N, et al.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2025 · Journal Article
Chautard R, Caulet M, Bouché O, Borg C, et al.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2025 · Journal Article
Delaye M, Boilève A, Henriques J, Rouault A, et al.
European journal of cancer (Oxford, England : 1990) · 2024 · Journal Article
Tougeron D, Bibeau F, Chibaudel B, Kim S, et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024 · Journal Article
Fosse A, Hadoux J, Girot P, Beron A, et al.
Liver international : official journal of the International Association for the Study of the Liver · 2024 · Journal Article
Lebeaud A, Antoun L, Paccard JR, Edeline J, et al.
Cancer imaging : the official publication of the International Cancer Imaging Society · 2024 · Clinical Trial
Mazard T, Mollevi C, Loyer EM, Léger J, et al.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2024 · Journal Article
Lecomte T, Tougeron D, Chautard R, Bressand D, et al.
Molecular pharmaceutics · 2024 · Journal Article
Roy M, Alix C, Burlaud-Gaillard J, Fouan D, et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024 · Journal Article
Al Mansour L, De Mestier L, Haissaguerre M, Afchain P, et al.
Cancer medicine · 2023 · Journal Article
Zwart K, van der Baan FH, Cohen R, Aparicio T, et al.
Cancer medicine · 2023 · Journal Article
Manfredi S, Dior M, Bouche O, Barbier E, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025 · Journal Article
Hammel P, Metges JP, Macarulla Mercade T, Garcia-Carbonero R, et al.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2025 · Journal Article
Bourien H, Adhoute X, Campillo-Gimenez B, Bouattour M, et al.
Diabetes & metabolism · 2026 · Journal Article
Dosda A, Fauchier G, Sabbah N, Fauchier L, et al.
Gastrointestinal endoscopy · 2026 · Journal Article
Pellat A, Manfredi S, Truant S, Roth G, et al.
Annals of surgical oncology · 2023 · Journal Article
Kalifi M, Deguelte S, Faron M, Afchain P, et al.
Therapeutic advances in medical oncology · 2025 · Journal Article
Valery M, Edeline J, Henriques J, Antoun L, et al.
Clinics and research in hepatology and gastroenterology · 2024 · Multicenter Study
Dardaine V, Cancel M, Inyambo K, Biogeau J, et al.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2025 · Journal Article
Bourien H, Adhoute X, Campillo-Gimenez B, Bouattour M, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · Journal Article
Cancel M, Sauger C, Biogeau J, Dardaine-Giraud V, et al.
Applying a Formal Method in Industry: a 25-Year Trajectory
Industrial applications involving formal methods are still exceptions to the general rule. Lack of understanding, employees without proper education, difficulty to integrate existing development cycles, no explicit requi
Low Cost High Integrity Platform
Developing safety critical applications often require rare human resources to complete successfully while off-the-shelf block solutions appear difficult to adapt especially during short-term projects. The CLEARSY Safety
Standardisation Considerations for Autonomous Train Control - Technical Report
This technical report is an extended version of conference submission to Safecomp 2022. We review software-based technologies already known to be, or expected to become essential for autonomous train control systems. It
Standardisation Considerations for Autonomous Train Control - Technical Report
This technical report is an extended version of conference submission to Safecomp 2022. We review software-based technologies already known to be, or expected to become essential for autonomous train control systems. It
Simultaneous or staged resection for synchronous liver metastasis and primary rectal cancer: a propensity score matching analysis
Abstract Background Colorectal cancer is the third most common cancer in France and by the time of the diagnosis, 15–25% of patients will suffer from synchronous liver metastases. Surgery associated to neoadjuvant treatm
The CLEARSY Safety Platform: 5 Years of Research, Development and Deployment
The CLEARSY Safety Platform (CSSP) was designed to ease the development of safety critical systems and to reduce the overall costs (development, deployment, and certification) under the pressure of the worldwide market.
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2025 · Letter
Giraudeau B, Ternant D, Lecomte T
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025 · Journal Article
Ducreux M, Desgrippes R, Rinaldi Y, Di Fiore F, et al.
The Lancet. Oncology · 2025 · Journal Article
Zaanan A, Bouché O, de la Fouchardière C, Le Malicot K, et al.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2025 · Clinical Trial Protocol
Lecomte T, Giraudeau B, Phelip JM, Tournigand C, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025 · Clinical Trial, Phase II
Walter T, Lecomte T, Hadoux J, Niccoli P, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · Randomized Controlled Trial
De La Fouchardière C, Malka D, Cropet C, Chabaud S, et al.